Alector Pharma launches Bydureon
Date: 06 Jul 2015

Alector has launched the new type 2 diabetes treatment Bydureon (exenatide) from AstraZeneca. Bydureon is administered once weekly. Exenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist which lowers blood glucose levels through increasing insulin secretion from the pancreas and reducing glucose production in the liver.

For more information please click here.